Evogene Financial Results and Earnings Announcement Schedule for the Second Quarter of 2021

REHOVOT, Israel , July 28, 2021 /PRNewswire/ — Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for the second quarter of 2021 on Wednesday, August 11th, 2021 . Ms. Sarit Firon Evogene’s incoming Chairperson of the Board, will join the conference call to discuss her vision for Evogene.

On the day of the announcement, the Company’s management will host a conference call to discuss the results at 09:00 AM Eastern time , 16:00 Israel time. To access the conference call, please dial +1-888-281-1167 toll free from the United States , or +972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company’s website at www.evogene.com .

A replay of the conference call will be available approximately two hours following the completion of the call. To access the replay, please dial +1-888-326-9310 toll free from the United States , or +972-3-925-5901 internationally. The replay will be accessible through August 13th, 2021 , and an archive of the webcast will be available on the webcast link for the following twelve months.

About Evogene Ltd.:

Evogene (NASDAQ: EVGN, TASE: EVGN) is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., and ag-solutions for castor oil production through Casterra Ltd. For more information, please visit www.evogene.com .

Evogene Investor Contact:
Aviva Banczewski / Rivka Neufeld
Investor Relations and Public Relations Manager
E: [email protected]
T: +972-8-931-1900

US Investor Relations:
Joseph Green
Edison Group
E: [email protected]
T: +1 646-653-7030

Laine Yonker
Edison Group
E: [email protected]
T: +1 646-653-7035

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.